TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Nasus Pharma Ltd. ( (NSRX) ).
On November 18, 2025, Nasus Pharma Ltd. announced the initiation of a Phase 2 clinical study for its intranasal epinephrine product, NS002, with the first participant dosed in Canada. This study aims to compare NS002’s bioavailability and pharmacokinetics against the EpiPen, offering a potential needle-free alternative for anaphylaxis treatment. The successful start of this trial marks a significant milestone for Nasus Pharma, as it positions itself for further growth by addressing the need for more user-friendly treatment options for severe allergies, potentially improving patient compliance and outcomes.
The most recent analyst rating on (NSRX) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Nasus Pharma Ltd. stock, see the NSRX Stock Forecast page.
More about Nasus Pharma Ltd.
Nasus Pharma Ltd. is a clinical-stage pharmaceutical company based in Tel Aviv, Israel, specializing in the development of innovative intranasal products for treating emergency medical conditions. The company focuses on providing needle-free alternatives for drug delivery, leveraging its proprietary powder-based intranasal technology for rapid and effective absorption, particularly in acute medical situations.
Average Trading Volume: 24,693
See more data about NSRX stock on TipRanks’ Stock Analysis page.